Interaction Checker

Irinotécan : interactions médicamenteuses

Irinotécan (Camptosar, Onivyde) présente 137 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 113 de niveau majeur, 21 de niveau modéré, 2 de niveau mineur et 1 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (113)

  • Acétazolamideinhibiteur de l'anhydrase carboniqueMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Acide étacryniquediurétique de l'anseMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Amiloridediurétique épargneur de potassiumMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • AmiodaroneantiarythmiqueMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Aprépitantinhibiteur du CYP3A4Majeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Armodafinilstimulant du SNCMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • AtazanavirantirétroviralMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Aténolol et chlortalidonebêtabloquantMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • AtropineanticholinergiqueMajeure

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (notice Irinotécan, Mise en garde encadrée)

  • Atropine et pralidoximeanticholinergiqueMajeure

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (notice Irinotécan, Mise en garde encadrée)

  • Bénazépril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Béthanécholagoniste cholinergiqueMajeure

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (notice Irinotécan, Mise en garde encadrée)

  • BisacodyllaxatifMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Bisoprolol et hydrochlorothiazidebêtabloquantMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Bosentaninducteur du CYP3A4Majeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Bumétanidediurétique de l'anseMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Candésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • CarbamazépineanticonvulsivantMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • CénobamateanticonvulsivantMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Cévimélineagoniste cholinergiqueMajeure

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (notice Irinotécan, Mise en garde encadrée)

  • Chlorothiazidediurétique thiazidiqueMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Chlortalidonediurétique thiazidiqueMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • CiclosporineimmunosuppresseurMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Cimétidineantihistaminique H2Majeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Clarithromycineantibiotique macrolideMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • ClobazambenzodiazépineMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • DarunavirantirétroviralMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Darunavir et cobicistatantirétroviralMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Déférasiroxsupplément de ferMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • DexaméthasonecorticoïdeMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Difénoxine et atropineMajeure

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (notice Irinotécan, Mise en garde encadrée)

  • Diltiazeminhibiteur calciqueMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Diphénoxylate et atropineMajeure

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (notice Irinotécan, Mise en garde encadrée)

  • DocusatelaxatifMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • DronédaroneantiarythmiqueMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • ÉfavirenzantirétroviralMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Éfavirenz, lamivudine et ténofovirantirétroviralMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Elvitégravir, cobicistat, emtricitabine et ténofovirantirétroviralMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Énalapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Éplérénoneantagoniste de l'aldostéroneMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Érythromycineantibiotique macrolideMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • EslicarbazépineanticonvulsivantMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • ÉtravirineantirétroviralMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • ÉvérolimusimmunosuppresseurMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Fluconazoleantifongique azoléMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • FosamprénavirantirétroviralMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Fosaprépitantinhibiteur du CYP3A4Majeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Fosinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • FosphénytoïneanticonvulsivantMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Furosémidediurétique de l'anseMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • GriséofulvineantifongiqueMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Hydrochlorothiazidediurétique thiazidiqueMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Imatinibinhibiteur du CYP3A4Majeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Indapamidediurétique thiazidiqueMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Irbésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • IsoniazideantibiotiqueMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Itraconazoleantifongique azoléMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Ivacaftorinhibiteur du CYP3A4Majeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Kétoconazoleantifongique azoléMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • LactuloselaxatifMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • LénacapavirantirétroviralMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Lisinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Lopéramidemédicament allongeant l'intervalle QTMajeure

    Late diarrhea can be life threatening and should be treated promptly with loperamide. (notice Irinotécan, Mise en garde encadrée)

  • Lopinavir et ritonavirantirétroviralMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Lorlatinibinducteur du CYP3A4Majeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Losartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Macrogol 3350laxatifMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Métolazonediurétique thiazidiqueMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Métoprolol et hydrochlorothiazidebêtabloquantMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Mifépristoneinhibiteur du CYP3A4Majeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Mirabégronagoniste bêta-adrénergiqueMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Mitapivatinducteur du CYP3A4Majeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Mitotaneinducteur du CYP3A4Majeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Modafinilstimulant du SNCMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Nafcillineantibiotique de la famille des pénicillinesMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • NéfazodoneantidépresseurMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • NévirapineantirétroviralMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Nirmatrelvir et ritonavirantiviralMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Olmésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • OxcarbazépineanticonvulsivantMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Palbociclibinhibiteur du CYP3A4Majeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • PérampanelanticonvulsivantMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • PhénobarbitalbarbituriqueMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Phénobarbital, hyoscyamine, atropine et scopolaminebarbituriqueMajeure

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (notice Irinotécan, Mise en garde encadrée)

  • Phentermine et topiramatestimulant du SNCMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • PhénytoïneanticonvulsivantMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Pilocarpineagoniste cholinergiqueMajeure

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (notice Irinotécan, Mise en garde encadrée)

  • Posaconazoleantifongique azoléMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • PrimidoneanticonvulsivantMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Pyridostigmineinhibiteur de la cholinestéraseMajeure

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (notice Irinotécan, Mise en garde encadrée)

  • Quinapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Ranolazinemédicament allongeant l'intervalle QTMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • RifabutineantibiotiqueMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • RifampicineantibiotiqueMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • RifapentineantibiotiqueMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • RitonavirantirétroviralMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • ScopolamineanticholinergiqueMajeure

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (notice Irinotécan, Mise en garde encadrée)

  • Séné (sennosides)laxatifMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Sofosbuvir et velpatasvirantiviralMajeure

    Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (notice Sofosbuvir et velpatasvir, Interactions médicamenteuses)

  • Spironolactoneantagoniste de l'aldostéroneMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Spironolactone et hydrochlorothiazideantagoniste de l'aldostéroneMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Suvorexantsédatif-hypnotiqueMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Suzétrigineinducteur du CYP3A4Majeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Telmisartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Ticagrélorantiagrégant plaquettaireMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • TopiramateanticonvulsivantMajeure

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Torasémidediurétique de l'anseMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Triamtérènediurétique épargneur de potassiumMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Triamtérène et hydrochlorothiazidediurétique épargneur de potassiumMajeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Valsartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Vérapamilinhibiteur calciqueMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

  • Voriconazoleantifongique azoléMajeure

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (notice Irinotécan, Interactions médicamenteuses)

Interactions modérées (21)

  • Acide valproïqueanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • BrivaracétamanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • Cannabidiol (sur ordonnance)anticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • CapécitabineantimétaboliteModérée

    Closely monitor for signs of renal toxicity when XELODA is used concomitantly with nephrotoxic drugs (e.g. platinum salts, irinotecan, methotrexate, intravenous bisphosphonates). (notice Capécitabine, Interactions médicamenteuses)

  • ClonazépambenzodiazépineModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • Divalproate de sodium (valproate)anticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • Eltrombopaginhibiteur de l'OATP1B1Modérée

    …(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (notice Eltrombopag, Interactions médicamenteuses)

  • ÉthosuximideanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • FelbamateanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • GabapentineanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • GemfibrozilfibrateModérée

    Coadministration of CAMPTOSAR with other inhibitors of CYP3A4 (e.g., clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or UGT1A1 (e.g., atazanavir, gemfibrozil, indinavir) may increase systemic exposure to irinotecan or SN-38. (notice Irinotécan, Interactions médicamenteuses)

  • LacosamideanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • LamotrigineanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • LévétiracétamanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • MésuximideanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • PrégabalineanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • Rolapitantinhibiteur du CYP2D6Modérée

    BCRP Substrates with a Narrow Therapeutic Index (e.g., methotrexate, topotecan, or irinotecan) Clinical Impact: Increased plasma concentrations of BCRP substrates (e.g., methotrexate, topotecan, or irinotecan) may result in potential adverse reactions [see Clinical Pharmacology (12.3) ]. (notice Rolapitant, Interactions médicamenteuses)

  • RufinamideanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • TiagabineanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • VigabatrineanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

  • ZonisamideanticonvulsivantModérée

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (notice Irinotécan, Interactions médicamenteuses)

Mentions mineures (2)

  • Acide foliniqueMineure

    5-Fluorouracil (5-FU) and Leucovorin (LV) In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. (notice Irinotécan, Interactions médicamenteuses)

  • FluorouracileantimétaboliteMineure

    5-Fluorouracil (5-FU) and Leucovorin (LV) In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. (notice Irinotécan, Interactions médicamenteuses)

Aucune interaction significative signalée (1)

  • BévacizumabAucune interaction

    Effects of VEGZELMA on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; however, 3 of the 8 patients receiving bevacizumab with paclitaxel and carboplatin had lower paclitaxel… (notice Bévacizumab, Interactions médicamenteuses)

Vérifiez Irinotécan avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.